Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Sidiqi, Hasib [1 ]
McGregor, Scott [2 ]
Baker, Ross [2 ]
Carnley, Ben [2 ]
Radeski, Dejan [1 ]
Barraclough, Allison [1 ]
Augustson, Bradley [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
[2] Perth Blood Inst, Perth, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-149
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [1] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [2] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [3] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S104 - S104
  • [5] Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis
    Farrell, James
    Bertin, Nicolas
    Fischer, Claire
    Gauthier, Aline
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S169 - S170
  • [6] Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
    Eleutherakis-Papaiakovou, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (11) : 921 - 928
  • [7] Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Dimopoulos, Meletios
    Palumbo, Antonio
    White, Darrell
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Moreau, Philippe
    Mateos, Maria-Victoria
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Spencer, Andrew
    Oakervee, Heather
    Orlowski, Robert Z.
    Taniwaki, Masafumi
    Roellig, Christoph
    Einsele, Hermann
    Wu, Ka Lung
    Singhal, Anil
    San-Miguel, Jesus
    Matsumoto, Morio
    Katz, Jessica
    Bleickardt, Eric
    Poulart, Valerie
    Anderson, Kenneth C.
    Richardson, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (07): : 621 - 631
  • [8] Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Lamb, Yvette N.
    DRUGS, 2018, 78 (14) : 1481 - 1488
  • [9] The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
    Nakayama, Hitomi
    Aisa, Yoshinobu
    Ito, Chisako
    Sakurai, Aki
    Nakazato, Tomonori
    HEMATOLOGY REPORTS, 2024, 16 (04) : 593 - 602
  • [10] Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Yvette N. Lamb
    Drugs, 2018, 78 : 1481 - 1488
12345